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Long-term misuse of zopiclone in an alcohol
dependent woman with a history of anorexia




Introduction: The Z-drugs, zaleplon, zopiclone and zolpidem, are short-acting hypnotics which act at the same
receptor as the benzodiazepines, but seemingly without the potential for misuse and the development of
dependence of the older benzodiazepines. However, with increased prescribing of Z-drugs, reports of misuse and
possible dependence began to appear in the literature, particularly in people with a history of substance misuse
and comorbid psychiatric illness. Here we report the case of a woman with a history of chronic zopiclone use and
anorexia nervosa, admitted for alcohol detoxification.
Case presentation: A 31-year old Caucasian British woman with a history of long-term zopiclone use and anorexia
nervosa was admitted as an inpatient for a ten-day alcohol detoxification. Her weekly (four days out of seven)
intake of alcohol was 180 units and her daily intake of zopiclone, 30 mg. Apart from a short period five years ago,
she had been taking zopiclone for 13 years at daily doses of up to 90 mg. She admitted to using ‘on top’ of her
prescribed medication, purchasing extra tablets from friends or receiving them gratis from her partner. After
detoxification from alcohol and zopiclone, she was prescribed diazepam which she found ineffectual and voiced
her intention of returning to zopiclone on leaving the hospital.
Conclusion: Zopiclone is generally regarded as safer than benzodiazepines, however, this particular individual, who
was using high doses of zopiclone over many years, may provide further evidence of a risk of dependency when
this drug is prescribed for substance users with a comorbid psychiatric illness.
Introduction
Insomnia is a subjective experience of poor or unre-
freshing sleep that may be apparent from a delayed
onset or decreased duration of sleep [1]. The short act-
ing hypnotic cyclopyrrolone derivative, zopiclone (RP
27,267) was synthesised in the late 1970 s and intro-
duced into clinical practice some ten years later. Zopi-
clone, like the other Z-drugs, zolpidem and zaleplon,
interacts with the same molecular target as the benzo-
diazepines on the GABAA (g-aminobutyric acid) recep-
tor [2,3]. Zopiclone is available as the racemic mixture
although the S-enantiomer, eszopiclone, has a 50 times
higher affinity for the receptor than the R-enantiomer
[4]. In terms of clinical efficacy and adverse reactions,
the Z-drugs showed little difference from the short act-
ing hypnotic benzodiazepines [5] although the fatality
toxicity index (deaths/10
6 prescriptions) for zopiclone,
2.1, was much lower than the 9.9 for temazepam [6].
When the Z-drugs were first introduced, there was lit-
tle epidemiological evidence of misuse; however, as time
went on, more cases began to appear in the literature.
In a report published in 1995 [7], zopiclone misuse was
identified in three male teenagers attending their local
CDAT (Community Drug and Alcohol Team). The
zopiclone had either been prescribed or bought on the
street (zim-zims) at a cost of £1 a tablet. In two indivi-
duals, zopiclone was being used to intensify and prolong
the effects of alcohol while the third, a polysubstance
user, was crushing up the tablets for intravenous injec-
tion. However, in none of the three was there any evi-
dence of dependence.
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tenance program at a Liverpool clinic, six admitted to
using zopiclone in daily doses up to 50 times the thera-
peutic dose over periods of between six and 24 months
[8]. All six had previously used temazepam but preferred
zopiclone because of its lack of amnesic side effects.
Zopiclone was readily obtainable from people who were
prescribed the drug or by forging prescriptions.
Am o r er e c e n ts t u d yo fi n d i v i d u a l so nam e t h a d o n e
maintenance program in Dublin found that 37 out of
158 (23%) tested positive for a zopiclone metabolite,
2-amino-5-chloropyridine, in the urine [9]. Benzodiaze-
pines were also present in the urine of just under 70%
of this group, none of whom were currently being pre-
scribed these drugs.
In a systematic review of the literature from 1996 to
2002, 22 cases of zopiclone abuse and 36 for zolpidem
were identified with doses used up to 51 (zopiclone) and
120 (zolpidem) times higher than those recommended
for insomnia [10]. The authors concluded that the two Z-
drugs were relatively safe compared to the hypnotic BZs
and both dependence following chronic use and addictive
non-medical use were quite rare although they did warn
of the possible risk to patients with a history of substance
use or mental illness. This warning has been confirmed
in later case reports of opioid-dependents injecting zolpi-
dem [11] and a cocaine user snorting zaleplon obtained
from several crushed capsules [12].
Case presentation
Our patient was a 31-year-old unemployed Caucasian
British woman with a diagnosis of alcohol dependence
(ICD-10, F10.2) who was referred to the Acute Assess-
ment Unit (AAU) of the hospital for a ten-day detoxifi-
cation by her local CDAT. On the 28 days immediately
prior to admission she had been drinking 6 L of cider
(7.5% ABV) equivalent to 45 units four times a week
and had been having blackouts as a result. High levels
of both aspartate transaminase (AST = 86 U/L) and g-
glutamyltransferase (gGT = 187 U/L) suggested possible
hepatic dysfunction but there was no evidence of cogni-
tive impairment (MMSE score = 29). On admission, she
was taking chlorpromazine (50 mg twice a day.) for
anxiety, fluoxetine (40 mg once daily) for low mood and
zopiclone (7.5 mg four times a day). Her physical health
screen did not reveal any abnormalities.
She had a long history of both anorexia nervosa and
alcohol dependence. Anorexia was first diagnosed in 1994,
and when she was 17 years old she was treated as an inpa-
tient. By the age of 18 years, her problem with alcohol had
become evident and over the intervening years she has
had six separate detoxifications with varying lengths of
abstinence; relapses being due to life events or trauma.
She also has a history of self-harm, overdosing, burning
and lacerating; her last admission to Accident and Emer-
gency was two years ago. Her father died of alcohol-related
problems and her uncles are also alcohol dependent. Her
sister had anorexia nervosa and died from cardiac compli-
cations, a common consequence of the severe calorific
deprivation associated with this eating disorder [13].
Zopiclone (7.5 mg nocte)w a sf i r s tp r e s c r i b e dt oh e l p
her to sleep when she was being treated for anorexia in
the rehabilitation unit. She found the calming effect of
taking it during the day highly desirable and when she
was discharged, asked her doctor to increase the dose,
claiming she had become tolerant of its hypnotic effect.
She reported a typical daily intake of 60 mg, but some-
times she used up to 90 mg, beginning when she woke
up and continuing throughout her waking cycle. Her
use of alcohol did not change throughout the time she
was taking zopiclone. Apart from prescribed zopiclone,
she obtained the drug from friends (paid for) and her
partner (donated).
Zopiclone was described as “her best friend” and like
alcohol it gave her confidence, relaxed her and enhanced
her self esteem. She said that she was ultra-possessive
about her supply and would not be separated from it,
keeping it with her at all times. During the 13 years of
using there had only been one relatively short period of
abstinence, which occurred six years ago, when she was in
the hospital for an alcohol and zopiclone detoxification.
However, this ended with the recurrence of the anorexia
and she was prescribed zopiclone to help her sleep.
The current detoxification followed the standard pro-
tocol used in the AAU, namely a tapering off of doses
of chlordiazepoxide (130 mg to zero over six days) and
on each of the first five days, an i.m. injection of Pabri-
nex® and thereafter Vitamin B Compound Strong tablets.
Her zopiclone was reduced from 7.5 mg nocte via 3.75
mg to zero over the same period as the chlordiazepoxide
after which she was started on diazepam 20 mg, with
the dose being reduced incrementally by 1 mg each day.
She found diazepam an ineffectual substitute and had
cravings for zopiclone and said she could not wait to
return to taking it as soon as possible. She had no inten-
tion of stopping zopiclone in the forseeable future.
Our patient is still off zopiclone (and alcohol) after 17
months although she continues to have strong cravings
for zopiclone (more so than for alcohol) which would
be easy to satisfy. She is concerned that zopiclone is not
considered addictive and that there is no specific proto-
col for detoxification, other than substitution with diaze-
pam, and help for understanding this addiction and
preventing relapse.
Discussion
After two decades of clinical use, the Z-drugs are con-
sidered to have a relatively low risk of being misused or
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hypnotics like temazepam. This was the conclusion
reached by Hayak et al. [10] on the basis of the number
of global prescriptions and a systematic Medline search
covering a seven-year period up to 2002. However, the
authors cautioned against their uncritical use in patients
with a history of substance misuse and/or psychiatric ill-
ness. A similar note of caution was sounded by Cimolai
[14] who identified 20 cases of dependence on zopiclone
(dose range 7.5 to 390 mg/d) in Canada between 1991
and 2006.
Dependence on alcohol may co-exist with dependence
on prescribed psychotropic drugs, thus complicating
clinical treatment. Johansson et al. [15] collected data
from a sample of alcohol dependents in both commu-
nity (n = 130) and inpatient (n = 23) settings in Sweden.
Seven percent of the outpatients and 13% of the inpati-
ents were found to be dependent on zopiclone or zolpi-
dem compared to 12% and 30% respectively for
benzodiazepines. However, the severity of dependence
as measured relative to the defined daily dose (DDD for
zopiclone = 7.5 mg, zolpidem = 10 mg) was between 1.0
and 1.5 (range of mean values for the two Z-drugs in
the two treatment settings) whereas for the benzodiaze-
pines, the values were 5.5 for outpatients and 11.5 for
inpatients; a value of ≥4.0 being considered high dose
dependence (HDD).
Using these values, our patient would be defined as
H D Dw i t hav a l u eo f1 2 .I no t h e rc a s es t u d i e so nz o p i -
clone dependence, ranges of 2 to 40 [9] and 1 to 51 [10]
have been noted. In one case described as ultrahigh
dose dependence, a 34-year old woman was taking zol-
pidem equivalent to 200 and when abruptly discontinu-
ing the drug, suffered withdrawal seizures [16].
In the Dublin sample, the mean age of onset and
duration of zopiclone use was 28 and 4.2 years respec-
tively with the mean age of the cohort being 32 years
[9]. From the review of the 22 cases of zopiclone
dependence, where the individual ages were presented
(n = 15), the mean age was 39 years [10]. Our patient
was 31 years old and although there are a few case
reports of zopiclone being taken at doses higher than
her typical daily intake of 60 mg, the 13 years of
almost continuous use might be considered particularly
unusual. It is also interesting to note that she had
every intention of returning to zopiclone as soon as
possible after discharge and that her experience with
benzodiazepines was considered inferior to zopiclone.
Comorbidity of alcohol dependence and anorexia ner-
vosa is common and a serotonergic neuronal dysfunc-
tion has been implicated in both disorders [17]. In our
patient, her cravings for zopiclone following withdra-
wal and interim substitution with diazepam would be
indicative of dependence. We would recommend a
cautious approach to prescribing Z-drugs to patients
with a dual diagnosis and that particular attention be
paid to any request for an increase in the daily dose.
Conclusion
We have described an individual with an atypically long
history of high dose dependence on zopiclone, alcohol
dependence and anorexia nervosa. This case adds
further support to the growing body of evidence that
prescribing zopiclone to drug users with an underlying
psychiatric disorder should be carefully monitored.
Patient’s perspective
Gratefully I’m still off zopiclone though I am aware I
could get hold of it easily. As yet, there’sn od e t o xf o r
coming off zopiclone. No help provided for the mental
or physical reasons and withdrawal.
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